Ann: First patient dosed in Phase 1/2 trial of CHM CDH17, page-5

And again the question is: How can ALA raise $$$ and attract buyers having still problems to get an IND for its iNKT CD 19 platform that only targets blood and skin cancers and that got more than 300 comps in that field doing R & D while CHM is the only one in the world going after solid gastro types that so far no comp has ever been able to attack successfully LT, got the IND, ethical approvals and already dosed the first patient but can't get any $$ raised and is valued crap.

Are we holders the most stupid investors the world has ever seen or will at some stage the market come to its senses? ALA EV $ 155m for nothing, CHM EV less than $ 10m having 4 trials and some complete responses on the score board.

GLTA